New Data Released at European Conference Demonstrates LuViva® Advanced Cervical Scan Detects Cervical Cancer Earlier than Pap and HPV tests
NORCROSS, Ga.–(BUSINESS WIRE)–Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that its Russian and Eastern European distribution partner, Newmars Group Kft., along with Hungarian physicians, reported new clinical results that demonstrate the early detection capability of the LuViva Advanced Cervical Scan. The study protocol was novel in that a positive LuViva test could result in a decision to biopsy a tissue sample to confirm the development of cervical cancer, even when the Pap and HPV tests were normal. In these cases, LuViva proved to be the more sensitive test, finding cervical cancer missed by Pap and HPV tests.
“…We were impressed by cases in which both the Pap and HPV tests were negative but LuViva was positive and the patient was later found by her biopsy result to be developing cervical cancer. This clearly demonstrates the value of LuViva for the early detection of cervical cancer.”
According to Dr. Zoltan Hernadi of the University of Debrecen in Hungary, “…We were impressed by cases in which both the Pap and HPV tests were negative but LuViva was positive and the patient was later found by her biopsy result to be developing cervical cancer. This clearly demonstrates the value of LuViva for the early detection of cervical cancer.”
The new data were initially reported at the Eurasian Cancer Screening Conference held in Minsk, Belarus on May 17-18, 2108. In the study, which showed results comparable to other studies conducted in the US and Europe, the sensitivity of LuViva was 100% (no false negatives) and 45% of women with a negative LuViva result could have avoided additional testing, including biopsy. The confidence that a woman with a negative LuViva result was free of cervical cancer was 100%, again consistent with previous studies.
“We are extremely pleased LuViva continues to perform exceptionally well in a variety of clinical settings and with different users working under a variety of protocols, including triage and primary screening,” said Gene Cartwright, CEO of Guided Therapeutics. “We look forward to launching the LuViva in Russia and Eastern Europe in the near future,” he added.
According to the World Health Organization, cervical cancer is ranked as one of the most frequent cancers in women. Central and Eastern Europe have a population of approximately 112 million women above 15 years of age, who are at risk of developing cervical cancer. The current estimates indicate approximately 1,971 per 100,000 new cases diagnosed and 886 per 100,000 deaths annually in Central and Eastern Europe, making the control of this deadly disease a priority for those countries.